[1] |
Fergeson JE, Patel SS, Lockey RF,et al.Acute asthma,prognosis,and treatment[J].J Allergy Clin Immunol,2017,139(2):438-447.
|
[2] |
Maltby S, McDonald VW, Upham JM,et al.Severe asthma assessment,management and the organisation of care in Australia and New Zealand:expert forum roundtable meetings[J].Intern Med J,2020.published online ahead of print February 27,2020]
URL
|
[3] |
Nanda A, Wasan AN.Asthma in adults[J].Med Clin North Am,2020,104(1):95-108.
|
[4] |
Fukuhara A, Saito J, Birring SS,et al.Clinical characteristics of cough frequency patterns in patients with and without asthma[J].J Allergy Clin Immunol Pract,2020,8(2):654-661.
|
[5] |
范韵鑫,张景熙,白冲.非典型主诉支气管哮喘临床诊断学特征及误诊分析[J/CD].中华诊断学电子杂志,2018,6(1):29-36.
|
[6] |
Moral L.Asthma diagnosis and lung testing:where is the boundary of asthma? [J].Allergol Immunopathol (Madr),2020,48(3):211-213.
|
[7] |
Breiteneder H, Peng YQ, Agache I,et al.Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma[J].Allergy,2020,75(12):3039-3068.
|
[8] |
Nguyen NV, Le AP, Chavannes NH. Combination of fractional exhaled nitric oxide (FeNO) level and asthma control test (ATC) in detecting GINA-defined asthma control in treated asthmatic patients in Vietnam[J].Can Respir J,2020,2020(56):1-9.
|
[9] |
Pifferi M, Bush A, Pioggia G,et al.Monitoring asthma control in children with allergies by soft computing of lung function and exhaled nitric oxide[J].Chest,2011,139(2):319-327.
|
[10] |
Booth A.Asthma guidelines:the best of three[J].Br J Nurs,2020,29(13):730-736.
|
[11] |
Lee K, Fujisawa T, Kim CK,et al.Biomarkers for recurrent wheezing and asthma in preschool children[J].Allergy Asthma Immunol Res,2019,11(1):16-28.
|
[12] |
Kreiβl S, Hendler S, Akmatov MK,et al.Reduced exhaled breath condensate pH and severity of allergic sensitization predict school age asthma[J].J Allergy Clin Immunol Pract,2020.published online ahead of print November 10 ,2020]
URL
|
[13] |
Zanconato S, Carraro S, Corradi M, et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma[J].J Allergy Clin Immunol,2004,113(2):257-263.
|
[14] |
Maniscalco M, Motta A.Clinical and inflammatory phenotyping:can electronic nose and NMR-based metabolomics work at the bedside?[J].Arch Med Res,2018,49(1):74-76.
|
[15] |
Eguiluz-Gracia I, Tay TR, Hew VM,et al.Recent developments and highlights in biomarkers in allergic diseases and asthma[J].Allergy,2018,73(12):2290-2305.
|
[16] |
Michalovich D, Rodriguez S, Smolinska S,et al.Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients[J].Nat Commun,2019,10(1):5711.
|
[17] |
Barcik W, Stoger L, Liu W,et al.Histamine-secreting microbes are increased in the gut of adult asthma patients[J].J Allergy Clin Immunol,2016,138(5):1491-1494.
|
[18] |
Kanaoka Y, Austen KF. Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions[J].Adv Immunol,2019(142):65-84.
|
[19] |
Salimi M, Stoger L, Liu W,et al.Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines[J].J Allergy Clin Immunol,2017,140(4):1090-1100.
|
[20] |
Marcello C, Carlo L.Asthma phenotypes:the intriguing selective intervention with Montelukast[J].Asthma Res Pract,2016(2):11.
|
[21] |
Wermuth HR, Badri T, Takov V.Montelukast[M].Treasure Island (FL):StatPearls Publishing,2020.
|
[22] |
Ueno H, Koya T, Takeuchi H,et al.Cysteinyl leukotriene synthesis via phospholipase A2 group IV mediates exercise-induced bronchoconstriction and airway remodeling[J].Am J Respir Cell Mol Biol,2020,63(1):57-66.
|
[23] |
Villeneuve T, Guilleminault L.Asthma and obesity in adults[J].Rev Mal Respir,2020,37(1):60-74.
|
[24] |
Garcia-Rio F, Alvarez-Puebla MJ, Esteban-Gorgojo I,et al.Obesity and asthma:key clinical questions[J].J Investig Allergol Clin Immunol,2019,29(4):262-271.
|
[25] |
Lazarinis N, Bood J, Gomez J,et al.Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor[J].J Allergy Clin Immunol,2018,142(4):1080-1089.
|
[26] |
Ujino M, Sugimoto N, Koizumi Y,et al.Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model[J].Allergol Int,2017(66S):S21-S26.
|
[27] |
Zuberi FF, Haroon MA, Haseeb A,et al.Role of montelukast in asthma and allergic rhinitis patients[J].Pak J Med Sci,2020,36(7):1517-1522.
|
[28] |
Dhaliwal A, Bajaj T. Zafirlukast[M]. Treasure Island (FL):StatPearls Publishing,2020.
|
[29] |
Lei C, Wu S, Wen C,et al.Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM)[J].Int Immunopharmacol,2019(68):68-73.
|
[30] |
Tamada T, Ichinose M.Leukotriene receptor antagonists and antiallergy drugs[J].Handb Exp Pharmacol,2017(237):153-169.
|
[31] |
朱韵倩,王兰兰,李文轩,等.呼出气一氧化氮检测在哮喘儿童孟鲁司特治疗中的应用价值[J/CD].中华诊断学电子杂志,2018,6(4):242-246.
|
[32] |
Hur J, Kang JY, Rhee CK,et al.The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling[J].Pulm Pharmacol Ther,2018(48):5-14.
|
[33] |
Wunder F, Tinel H, Kast R,et al.Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor[J].Br J Pharmacol,2010,60(2):399-409.
|
[34] |
Trinh HKT, Suh DH, Nguyen TVT,et al.Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma[J].Prostaglandins Leukot Essent Fatty Acids,2019(141):17-23.
|
[35] |
Ni NC, Yan D, Ballantyne LL,et al.A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice[J].J Pharmacol Exp Ther,2011,339(3):768-778.
|
[36] |
Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand[J].J Biol Chem,2013,288(16):10967-10972.
|
[37] |
White AA, Stevenson DD.Aspirin-exacerbated respiratory disease[J].N Engl J Med,2018,379(11):1060-1070.
|
[38] |
Sekioka T, Kadode M, Fujii M,et al.Expression of CysLT2 receptors in asthma lung,and their possible role in bronchoconstriction[J].Allergol Int,2015,64(4):351-358.
|
[39] |
Itadani S, Yashiro K, Aratani Y,et al.Discovery of gemilukast (ONO-6950),a dual CysLT1 and CysLT2 antagonist as a therapeutic agent for asthma[J].J Med Chem,2015,58(15):6093-6113.
|
[40] |
Montuschi P, Sala A, Dahlén SE,et al.Pharmacological modulation of the leukotriene pathway in allergic airway disease[J].Drug Discov Today,2007,12(9-10):404-412.
|